Synthetic Biologics Inc (SYN) Announces Quarterly Earnings Results
Synthetic Biologics Inc (NYSEMKT:SYN) posted its quarterly earnings results on Wednesday. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.04) by ($0.10), Bloomberg Earnings reports.
TRADEMARK VIOLATION WARNING: “Synthetic Biologics Inc (SYN) Announces Quarterly Earnings Results” was first reported by American Banking News and is owned by of American Banking News. If you are reading this piece of content on another website, it was illegally copied and reposted in violation of U.S. & international copyright legislation. The original version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/11/02/synthetic-biologics-inc-syn-announces-quarterly-earnings-results.html.
Several brokerages have recently weighed in on SYN. Zacks Investment Research upgraded shares of Synthetic Biologics from a “hold” rating to a “buy” rating and set a $0.75 target price on the stock in a research report on Wednesday, August 9th. ValuEngine upgraded shares of Synthetic Biologics from a “strong sell” rating to a “sell” rating in a research report on Friday, August 18th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and two have given a buy rating to the company’s stock. Synthetic Biologics has a consensus rating of “Hold” and a consensus price target of $3.92.
Synthetic Biologics Company Profile
Synthetic Biologics, Inc is a clinical-stage company. The Company is engaged in developing therapeutics to protect the gut microbiome while targeting pathogen-specific diseases. The Company’s lead product candidates in Phase II development are SYN-010, which is intended to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C), and SYN-004, which is designed to protect the gut microbiome (gastrointestinal (GI) microflora) from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C.
Receive News & Ratings for Synthetic Biologics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synthetic Biologics Inc and related companies with MarketBeat.com's FREE daily email newsletter.